Gadolinium-based agents are used in approximately 34%* of MRI scans, including MRA exams.
A key advantage of MR Angiography is that it can be performed without the use of a contrast agent. Recent advancements with scanner hardware, acceleration in image acquisition and techniques designed to increase SNR have made non-contrast MRA more of a routine diagnostic option.
For the first few decades of MR's existence, it was believed that MRI contrast agents were entirely safe to administer, even when double and triple dosed for MRA exams. However, in 2006, this belief was challenged when gadolinium-based agents were directly linked to Nephrogenic Systemic Fibrosis, a potentially lethal disease. Deposition of gadolinium in vital organs, such as the brain, liver and kidneys is also of concern.Enter Escape Room *IMV 2021 MR Market Outlook Report